Our ex vivo Skin Model is used to test lead formulations and screen them against a variety of parameters to ensure clinical success.
Our ex vivo models are customizable and can offer preclinical testing to fast track your product to market. We perform antimicrobial efficacy testing, biomarker assessments, and host cell toxicity on wounded or unwounded skin.
- To assess inflammation we treat and incubate intact skin, take biopsies from the treated intact skin, and then perform ELISAs or cytokine panel assays to determine quantities of biomarkers.
- To test for efficacy against known human pathogens, experiments are typically performed on wounded skin explants. These explants are prepared by removing a small amount of epidermis from the center of a larger explant. The depth and size of these explants and wounds are customizable.
- We also assess wound healing in the wounded skin model. At specific timepoints post-treatment, we analyze the biomarkers present in wounds and couple that data with histology.
Relevant Therapeutic Areas
By engineering wounds in our human skin model, we can investigate the wound-healing capabilities of your formulations by performing large screens of analytes predictive of wound healing in conjunction with histology.
Inflammation and Biocompatibility
Our human skin model is an excellent way to examine the influence of your experimental product on inflammation. Our wounded or intact human skin models will help determine whether your compounds have pro- or anti-inflammatory properties.
Using our human skin model, we can perform research on known human pathogens. The most common organisms we use are methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. Infections can be planktonic or biofilm.